About Oral Cancer Foundation News Team - A

This author has not yet filled in any details.
So far Oral Cancer Foundation News Team - A has created 2444 blog entries.

Alcohol consumption increases risk for seven types of cancer: Study

Source: perfscience.com Author: Diana Bretting An analysis of past health studies that have looked at the association between drinking and cancer has unveiled that having alcoholic beverages can increase the risk for seven types of cancer, including head, neck, esophageal, liver, colorectal and breast cancer. The analysis carried out by Jennie Connor of the University of Otago, in New Zealand included comprehensive reviews conducted by the prestigious organizations, which include the World Cancer Research Fund and the American Institute for Cancer Research among others. The researchers came to know that the risk did not go down even if there were different alcohol types like rum, whiskey, wine or beer. The risk increases with higher consumption, which as per the researchers is known as a dose-response relationship. Connor was of the view that there is little evidence suggesting that the risk lessens for head and neck and liver cancers when consumption declines. Dr. Susan Gapstur, Vice-President of the Epidemiology Research Program at the American Cancer Society, said that the analysis has strengthened what is already known about the link between alcohol and cancer. Dr. Gapstur said, “This is a review of an existing body of literature. Essentially the author has interpreted the literature to help people to understand. But it's not a study of any new data. These seven cancer sites have long been established”. Health officials were of the view that the study might help regular drinkers to cut their drinking habit. Dr. Jana Witt, of Cancer Research UK said [...]

2016-07-27T11:42:47-07:00July, 2016|Oral Cancer News|
Read More

Despite medical backing, HPV vaccine rates remain low amid sexual and moral controversy

Source: www.omaha.com Author: Rick Ruggles, World-Herald staff writer The HPV vaccine can reduce the rates of certain cancers, including many cervical and oral cancers, physicians and medical organizations say. But opposition by some individuals is strong, and HPV vaccination rates remain low when compared with other kinds of vaccinations recommended for adolescents. Because the human papillomavirus is sexually transmitted and seventh grade is considered the ideal time to receive the three-dose vaccine regimen, the issue is rife with sexual and moral implications. Perhaps more potent today, though, are Internet horror stories and concerns about side effects. A World-Herald Facebook request for views on the HPV vaccine generated far more negatives than positives. “NO NO & NO!! There is NO reason for this vaccine,” one wrote. Another called it a “deadly shot.” Two Omaha mothers who were interviewed expressed their belief that it’s wise to have children vaccinated, and said their kids suffered no side effects. But an Iowa man described health problems suffered by his daughter, and he and an Ohio physician believe the girl was injured by the HPV vaccinations. So mediocre are HPV vaccination rates that GSK, the maker of Cervarix, plans to cease distribution of its HPV vaccine in the United States in September. It will continue to supply it in many other nations, such as Great Britain, Germany, France and Mexico. The departure of Cervarix leaves the market to Gardasil, a vaccine produced by Merck. “GSK has made the decision to stop supplying Cervarix ... in [...]

2016-07-24T12:18:56-07:00July, 2016|Oral Cancer News|
Read More

Rate of HPV-associated cancers on the rise in U.S., according to new CDC report

Source: www.curetoday.com Author: Andrew J. Roth Though the first preventive human papilloma virus (HPV) vaccine was approved by the U.S. Food and Drug Administration 10 years ago, the incidence of HPV-associated cancers is on the rise. From 2008 to 2012, the number of HPV-associated cancers diagnosed per year increased by approximately 16 percent compared with the previous five-year period, according to a new report by the Centers for Disease Control and Prevention (CDC). Nearly all sexually active individuals in the U.S. will get at least one type of HPV in their lifetime, making it the most common sexually-transmitted infection in the country. And though about 90 percent of HPV infections will clear a person’s system within two years, some infections persist and can cause cervical cancers and some types of vulvar, oropharyngeal, penile, rectal and cancers. There are over 40 HPV types, and vaccines are available for HPV types 16 and 18 (which account for 63 percent of HPV-associated cancers), as well as for types 31, 33, 45, 52 and 58 (which account for an additional 10 percent). Type 16 is the most likely to persist and develop into cancer. In this new report, the CDC analyzed data from its own National Program of Cancer Registries as well as the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database. In total, 38,793 HPV-associated cancers (11.7 per 100,000 persons), on average, were diagnosed annually from 2008 to 2012 compared with 33,369 diagnoses (10.8 per 100,000 persons) from 2004 to 2008. [...]

2016-07-16T15:47:18-07:00July, 2016|Oral Cancer News|
Read More

HPV-related cancer Is ‘epidemic’—but few get vaccinated

Source: www.newser.com Author: Michael Harthorne, Newser Staff "Every parent should ask the question: If there was a vaccine I could give my child that would prevent him/her from developing six different cancers, would I give it to them?” Electra Paskett, co-director of the Cancer Control Research Program at Ohio State University, tells CBS News. The answer appears to be no. According to NBC News, a CDC report released Thursday shows a 17% increase in HPV-related cancers between 2004 and 2012 to nearly 39,000 per year. Dr. Lois Ramondetta, an expert in gynecologic oncology, says it's become an "epidemic" especially for men, in whom HPV can cause cancers of the mouth, tongue, and throat. HPV increases the risk of those cancers by at least seven times, and unlike with HPV-caused cervical cancer in women, there's no screening for them. The CDC report found 93% of all HPV-related cancers could be prevented with the currently available vaccine. That's approximately 28,500 fewer cases of cancer every year, AFP reports. And yet in 2014, only 40% of teen girls and 22% of teen boys received the necessary three doses of the vaccine, which works best if administered before teens become sexually active. Paskett calls those numbers "extremely sad." “We must change the perception of the HPV vaccine from something that prevents a sexually transmitted disease to a vaccine that prevents cancer," she tells CBS. (Some British teens invented condoms that change color near HPV and other STDs.)

2016-07-11T21:21:07-07:00July, 2016|Oral Cancer News|
Read More

HPV vaccine important preventive tool for survivors of childhood cancer

Source: www.curetoday.com Author: Ellie Leick As childhood cancer survivors are at an increased risk of developing second cancers later in life, James Klosky recommends that this population receive the human papillomavirus (HPV) series of vaccines. A survey of 679 survivors one to five years out of treatment was conducted to evaluate how many received the vaccine compared with their healthy peers. A great disparity was discovered, as survivors — all of whom were between age 13 and 26 — were less likely to receive the vaccine. Researchers also investigated the reasons why many survivors did not receive it. Klosky, an associate member and director of psychological services in cancer survivorship at St. Jude Children’s Research Hospital, presented the findings from this research at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), a gathering of 30,000 oncology professionals in Chicago. CURE spoke with Klosky at the meeting to discuss the key takeaways and the importance of the HPV vaccine to survivors of childhood cancer. Can you give an overview of the study and its purpose? The HPV vaccine is the first vaccine that’s designed to prevent cancers. We are particularly interested in the application of this vaccine amongst survivors of childhood cancers, who are at increased risk for HPV-related cancers in young adulthood relative to their healthy peers. On average, the onset of these cancers occur seven years earlier in survivors of childhood cancers compared to their healthy peers. Additionally, survivors of childhood cancer have an increased [...]

2016-07-01T19:47:53-07:00July, 2016|Oral Cancer News|
Read More

New study analyzes physical therapy for head and neck cancer survivors

Source: www.curetoday.com Author: Andrew J. Roth The aftermath of treatment for head and neck cancer can be particularly difficult, according to Ann Marie Flores. Flores, assistant professor, Department of Physical Therapy, Movement & Rehabilitation Science, Bouvé College of Health Sciences, Northeastern University, conducted a pre-pilot study looking at early physical therapy education for this patient population. CURE interviewed Flores about her poster, which she presented at the 8th Biennial Cancer Survivorship Research Conference in Washington, DC. Could you first give some background about this study? How did it come to be? It was a spinoff of some studies that I began in breast cancer. I conducted a literature review of rehab needs of breast cancer survivors about 10 years ago and found that there was very little out there. Then, when I started a rehab oncology program at a previous institution, the patient population that were referred to the program tended to not be breast cancer patients, because they physically and functionally tend to do well in aggregate. Most of my patients referred were those with head and neck cancer. I went through the same process to look through literature critically to figure out what exists in terms of physical therapy and rehabilitation-based approaches. I've updated this over a long period of time and this poster is a systematic review of the quality of evidence. I combined this literature and data review with talking to a focus group of cancer survivors. What did you find? I asked the focus group [...]

2016-06-26T08:37:15-07:00June, 2016|Oral Cancer News|
Read More

HPV vaccination could be offered to schoolboys to decrease risk of cancer

Source: www.mirror.co.uk Author: Andrew Gregory A vaccination could soon be offered to every schoolboy to help tackle the rising rate of some cancers in men, a Government minister revealed on Thursday. Health chiefs are poised to drop their opposition to extending the jab to protect against the human papilloma virus (HPV), which is already given to all Year 8 girls. The likely move follows growing alarm over cancers of the mouth, throat, neck and head, as well as penile and anal cancer, amid growing evidence that they are caused by HPV. The NHS (National Health Service) spends more than £300m a year treating head and neck cancers, while giving the vaccine to all boys would cost just £22m, supporters say. Health Minister Jane Ellison has revealed that the independent Joint Committee on Vaccination and Immunization (JCVI) is investigating the change, with its verdict due early next year. Mrs Ellison - who has previously described giving the HPV jab to girls only as "a little odd" - said: "I understand the wish for it to be available to all adolescents regardless of gender. "The JCVI is reconsidering its initial advice on this and modeling is under way to inform its consideration. We will look at that as a priority when we get it. "I recognize the frustration that people have expressed and I have talked personally to Public Health England officials who are involved in the modelling work." The minister said money was already available to extend the vaccination program if [...]

2016-06-26T08:27:30-07:00June, 2016|Oral Cancer News|
Read More

Number of circulating tumor cells up after surgery in SCCHN

Source: www.doctorslounge.com Author: staff Most patients with squamous cell carcinoma of the head and neck (SCCHN) have an increase in the number of circulating tumor cells (CTCs) after surgical resection, according to a study published online June 5 in Head & Neck. Kris R. Jatana, M.D., from the Nationwide Children's Hospital in Columbus, Ohio, and colleagues identified cytokeratin-positive CTCs using a negative depletion technique. They compared the numbers of CTCs immediately before and after surgical resection using blood samples from 38 patients with SCCHN. The researchers found that 79 percent of patients had CTCs before and after surgery. Overall, 7.89 percent of patients had no CTCs before surgery but did have CTCs after surgery. After surgery there was an increased number of CTCs/mL in 60.5 percent of patients, with a 6.63-fold mean increase (P = 0.02). "The timing of blood sample collection for such solid cancers that undergo surgical intervention, such as SCCHN, can potentially impact the number of CTCs identified," the authors write. "Although a prognostic blood test for CTCs could have important treatment and surveillance implications, the viability and clinical significance of potentially surgically released CTCs in SCCHN is still not known."

2016-06-18T08:23:27-07:00June, 2016|Oral Cancer News|
Read More

Heading back to the office following head and neck cancer

Source: blogs.biomedcentral.com Author: Daniel Caley In Cancers of the Head & Neck launching today publishes the first study looking at disability and employment outcomes in patients with head and neck cancer related to the human papillomavirus (HPV). Dr Shrujal Baxi, Section Editor for survivorship and patient related outcomes and author of this study, explains more about their work in this Q&A: The rates of patients diagnosed with HPV-related head and neck cancer is rising annually. By 2020, there will be more cases of HPV-related head and neck cancer than HPV-related cervical cancer in the United States. Numerous studies have shown that most patients with this diagnosis are likely to be cured of their disease, placing an increased emphasis on quality of life and non-cancer outcomes in this population of survivors. The majority of patients diagnosed with HPV-related head and neck cancer are working-age adults and employment is a serious issue both financially and psychologically. How can treatment for head and neck cancer impact employment? Treatment for head and neck cancer often involves a combination of chemotherapy and radiation given over a six to seven week period, often known as concurrent chemoradiation or combined modality chemoradiation. This process is considered toxic and can impact a patient’s ability to function normally including speaking, chewing, breathing and swallowing. Many patients require numerous supportive medications to get through treatment including narcotics for pain and anti-nausea medications. Patients can lose on average 10-15% of their weight within a few months and can suffer from severe [...]

2016-06-05T09:53:53-07:00June, 2016|Oral Cancer News|
Read More

Type 2 diabetes drug could be beneficial for head and neck cancer patients

Source: www.eurekalert.org Author: press release Researchers at the University of Cincinnati (UC) College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial. These findings are being presented via poster June 4 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting: Collective Wisdom, being held June 3-7 in Chicago. Trisha Wise-Draper, MD, PhD, assistant professor in the Division of Hematology Oncology at the UC College of Medicine, a member of both the Cincinnati Cancer Center and UC Cancer Institute and principal investigator on this study, says retrospective studies have shown improved outcomes in tumors treated with chemotherapy and radiation if they were also on metformin for diabetes. "In head and neck squamous cell carcinoma, which develops in the mucous membranes of the mouth, nose and throat, diabetic patients taking a medication called metformin had better overall survival compared to those not on metformin when also treated with chemotherapy and radiation," she says. "Additionally, pancreatic cancer patients treated with chemotherapy and metformin required higher doses of metformin--1,000 milligrams twice a day--to experience positive results. "In basic science studies, metformin has been shown to stop mTOR, a molecular pathway present and active in this type of head and neck cancer, and pretreatment with metformin resulted in a decrease in the occurrence of oral cavity tumors in [...]

2016-06-05T09:30:41-07:00June, 2016|Oral Cancer News|
Read More
© - The Oral Cancer Foundation - Head & Neck Cancer IRS 501(c)3 Charity - 3419 Via Lido #205, Newport Beach, CA 92663 | Disclaimer / Privacy Policy
Go to Top